

November 1, 2013

VIA EDGARUnited States Securities and Exchange Commission
Washington, D.C. 20549Attention: Jim B. Rosenberg, Senior Assistant Chief Accountant
Division of Corporate FinanceRe: Jazz Pharmaceuticals plc
Form 10-K for the Fiscal Year Ended December 31, 2012
Filed February 26, 2013
Form 10-Q for the Quarterly Period Ended June 30, 2013
Filed August 6, 2013
Form 8-K dated August 6, 2013
Filed August 6, 2013
File No. 001-33500

Dear Mr. Rosenberg:

On behalf of Jazz Pharmaceuticals plc (the "Company"), this letter is being transmitted to inform the staff of the Securities and Exchange Commission (the "Staff") that the Company intends to respond to the Staff's letter dated October 22, 2013 with respect to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2012, the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2013 and the Company's Form 8-K dated August 6, 2013, no later than November 15, 2013.

Please do not hesitate to contact the undersigned at (650) 496-2654 if you have any questions or would like additional information regarding this matter.

Sincerely,

/s/ Karen J. Wilson

Karen J. Wilson
Senior Vice President, Finance and Principal Accounting
Officer
Jazz Pharmaceuticals plc

cc: Suzanne Sawochka Hooper, *Jazz Pharmaceuticals plc*
Valerie Pierce, *Jazz Pharmaceuticals plc*
Chadwick Mills, *Cooley LLP*